New marker shows which bladder cancer patients benefit from therapy
Researchers at the Helmholtz-Zentrum Dresden-Rossendorf have developed a molecular marker to help doctors choose the right bladder cancer therapy. The radiotracer NECT-224 makes visible whether tumors carry a certain protein to which modern drugs can dock. In summer 2025, it was used successfully for the first time on a patient at Dresden University Hospital.